LAVA Therapeutics N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LVTX research report →
Range $1.5 – $6
Price Chart
About the company
LAVA Therapeutics N. V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer.
- CEO
- Stephen Allen Hurly
- IPO
- 2021
- Employees
- 34
- HQ
- Utrecht, NL
Get TickerSpark's AI analysis on LVTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.77M
- P/E
- -2.42
- PEG
- -0.18
- P/S
- 0.00
- P/B
- 3.69
- EV/EBITDA
- 0.21
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -99.17%
- ROIC
- -47.04%
Latest fiscal year · YoY change
- Revenue
- $11.98M+77.0%
- Gross Profit
- $11.98M+264.5%
- Op Income
- $-29,693,000
- Net Income
- $-25,114,000+40.0%
- EPS
- $-0.94+40.1%
- OCF Growth
- +51.5%
- FCF Growth
- +52.3%
- 52W High
- $2.00
- 52W Low
- $0.85
- 50D MA
- $1.59
- 200D MA
- $1.39
- Beta
- 0.50
- RSI (14)
- 63
- Avg Volume
- 346.58K
No earnings-call transcripts are available for LVTX yet.
- Free Float
- 46.9%
- Shares Outstanding
- 26.31M
- Float Shares
- 12.34M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cutler Group LLC / Ca | 1.00K | ▲ 1.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 25 | Powell Fred M | sell | 124,700 |
| Nov 13, 25 | Powell Fred M | sell | 65,000 |
| Nov 13, 25 | Wadlinger Mary E. | sell | 33,390 |
| Nov 13, 25 | Oliger Christy J. | sell | 33,390 |
| Nov 13, 25 | Noble James | sell | 33,390 |
| Nov 13, 25 | Kiener Peter A | sell | 33,390 |
| Nov 13, 25 | Backstrom Jay T. | sell | 33,390 |
| Nov 13, 25 | WILSON KAREN J | sell | 33,390 |
| Nov 13, 25 | WILSON KAREN J | sell | 10,000 |
| Nov 13, 25 | Dhingra Kapil | sell | 33,390 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LVTX coverage
Recent articles, reports, and earnings notes.
No research on LVTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LVTX report →LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts
defenseworld.net · Dec 8
Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69
defenseworld.net · Nov 16
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
gurufocus.com · Nov 13
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
globenewswire.com · Nov 13
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
globenewswire.com · Nov 10
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
prnewswire.com · Oct 20
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.